Abdullah Al Mamun Khan, Muhammed Jahangir Alam, Parvin Shahida Akhtar
{"title":"MO20-5 Five-year survival rate of AYA patients from sarcoma: A prospective fixed cohort study in Bangladesh","authors":"Abdullah Al Mamun Khan, Muhammed Jahangir Alam, Parvin Shahida Akhtar","doi":"10.1016/j.annonc.2023.09.206","DOIUrl":null,"url":null,"abstract":"Survivors of adolescent and young adult cancers (AYA) often live 50 to 60 years beyond their diagnosis but a few clinical and epidemiological data from developing countries. Sarcoma is a leading and worst malignancy that may manageable if diagnosed early.","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"61 6","pages":"0"},"PeriodicalIF":56.7000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.annonc.2023.09.206","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Survivors of adolescent and young adult cancers (AYA) often live 50 to 60 years beyond their diagnosis but a few clinical and epidemiological data from developing countries. Sarcoma is a leading and worst malignancy that may manageable if diagnosed early.
期刊介绍：
Annals of Oncology, the official journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, offers rapid and efficient peer-reviewed publications on innovative cancer treatments and translational research in oncology and precision medicine.
The journal primarily focuses on areas such as systemic anticancer therapy, with a specific emphasis on molecular targeted agents and new immune therapies. We also welcome randomized trials, including negative results, as well as top-level guidelines. Additionally, we encourage submissions in emerging fields that are crucial to personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Manuscripts related to radiotherapy, surgery, and pediatrics will be considered if they demonstrate a clear interaction with any of the aforementioned fields or if they present groundbreaking findings.
Our international editorial board comprises renowned experts who are leaders in their respective fields. Through Annals of Oncology, we strive to provide the most effective communication on the dynamic and ever-evolving global oncology landscape.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
